Otilonium Bromide: High-Purity Antimuscarinic Agent for Neuroscience Research

Executive Summary: Otilonium Bromide (SKU B1607) is an antimuscarinic agent with ≥98% purity, designed for scientific research applications. It inhibits acetylcholine receptors (AChR), making it a reliable tool for studies of cholinergic signaling and smooth muscle physiology (APExBIO). Its high solubility in DMSO, water, and ethanol supports diverse experimental setups. The compound is supplied by APExBIO and should be stored at -20°C for optimal stability. Otilonium Bromide is not approved for diagnostic or therapeutic use, strictly limiting its application to laboratory research (Vijayan et al., 2021).

Biological Rationale

Otilonium Bromide is a synthetic antimuscarinic agent with the chemical formula C₂₉H₄₃BrN₂O₄ and a molecular weight of 563.57 g/mol (APExBIO). It is primarily used in neuroscience and pharmacology research to dissect cholinergic signaling pathways. Muscarinic acetylcholine receptors (AChRs) are G protein-coupled receptors that mediate the effects of acetylcholine in smooth muscle, the central nervous system, and peripheral tissues. Dysregulation of these pathways contributes to gastrointestinal motility disorders and smooth muscle spasms. The ability to selectively inhibit AChRs enables precise modeling of these physiological and pathological processes (Related: Streamlining Workflows—this article presents updated solubility data and detailed handling parameters not covered in previous summaries).

Mechanism of Action of Otilonium Bromide

Otilonium Bromide acts as a competitive antagonist at muscarinic acetylcholine receptors. By binding to these receptors, it blocks the action of endogenous acetylcholine, thereby inhibiting cholinergic neurotransmission. This mechanism results in a decrease in smooth muscle contractility, conferring potent antispasmodic effects. The compound's efficacy is attributed to its high affinity for muscarinic receptors and its ability to modulate receptor-mediated physiological responses without directly affecting non-cholinergic pathways. In vitro studies confirm that Otilonium Bromide does not significantly interact with nicotinic acetylcholine receptors under standard experimental conditions, supporting its selectivity profile (Vijayan et al., 2021).

Evidence & Benchmarks

• Otilonium Bromide demonstrates ≥98% purity as verified by HPLC and NMR, enabling reproducible results in receptor modulation assays (APExBIO).
• Solubility benchmarks: ≥28.18 mg/mL in DMSO, ≥55.8 mg/mL in water, and ≥91 mg/mL in ethanol; all measurements at 20°C and pH 7.4 (APExBIO).
• Inhibition of muscarinic AChR-mediated contractions in smooth muscle tissue is dose-dependent and reversible (see related data: High-Purity Agent Applications—this article offers workflow integration strategies, which are extended here with updated solubility and purity metrics).
• Optimal storage at -20°C preserves compound stability for at least 12 months when desiccated and protected from light (APExBIO).
• Not approved for therapeutic use; intended exclusively for research purposes (Vijayan et al., 2021).

Applications, Limits & Misconceptions

Otilonium Bromide is widely used in the following research applications:

• Modeling cholinergic signaling in central and peripheral nervous system assays.
• Investigating gastrointestinal motility disorders and smooth muscle spasm mechanisms.
• Benchmarking antispasmodic pharmacology protocols.
• Dissecting muscarinic receptor-mediated pathways in ex vivo and in vitro models.

For advanced troubleshooting, see: Advanced Use-Cases & Protocols—this article is extended here with quantitative solubility, stability, and regulatory clarifications.

Common Pitfalls or Misconceptions

• Otilonium Bromide is not suitable for diagnostic or clinical applications; using it outside of laboratory research is prohibited.
• It does not inhibit nicotinic acetylcholine receptors under standard concentrations (≤10 µM).
• The compound is light-sensitive; improper storage can result in degradation and loss of activity.
• Stock solutions in aqueous buffers should be used promptly (within 24 hours) to ensure chemical stability.
• Conflating Otilonium Bromide with non-selective antispasmodics may lead to misinterpretation of data; its mechanism is receptor-specific.

Workflow Integration & Parameters

Otilonium Bromide is supplied as a solid powder and should be dissolved in DMSO, water, or ethanol depending on experimental requirements. The recommended stock concentration is 10–50 mM, filtered for sterility. For cell-based assays, the compound should be diluted to final working concentrations of 0.1–10 µM. Solutions are stable for up to one week at -20°C (protected from light); however, freshly prepared aliquots are recommended for critical experiments. The product's high solubility simplifies protocol integration, supporting automated liquid handling systems and high-throughput screening. For details on reproducibility and troubleshooting, consult: Scenario-Driven Q&A—expanded here with enhanced solution handling guidance.

Conclusion & Outlook

Otilonium Bromide (from APExBIO) is a validated, high-purity antimuscarinic agent optimized for cholinergic signaling and smooth muscle research. Its well-characterized solubility, selectivity, and workflow compatibility establish it as a standard for neuroscience and gastrointestinal motility disorder models. As research advances, careful adherence to storage and handling guidelines will maximize reproducibility and data integrity. Ongoing studies continue to refine the use of AChR inhibitors for dissecting receptor-mediated processes in both health and disease (Vijayan et al., 2021).